| Print
Spruce Biosciences Inc (SPRB)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Address
251 Little Falls Drive
County of New Castle
Wilmington
DE
USA
19808
Forecast key dates
| Name | Key Date |
|---|---|
| Spruce Biosciences Inc Fourth Quarter Earnings Results for 2026 | 2027-03-09T00:00:00 |
| Spruce Biosciences Inc Annual Report for 2026 | 2027-03-09T00:00:00 |
| Spruce Biosciences Inc Third Quarter Earnings Results for 2026 | 2026-11-10T00:00:00 |
| Spruce Biosciences Inc Second Quarter Earnings Results for 2026 | 2026-08-14T00:00:00 |
| Spruce Biosciences Inc Annual General Meeting for 2026 | 2026-06-09T10:00:00 |
| Spruce Biosciences Inc First Quarter Earnings Results for 2026 | 2026-05-06T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| The Citizens Life Sciences Conference | 2026-03-10T12:30:00 |
| Leerink Global Healthcare Conference | 2026-03-09T11:20:00 |
| Spruce Biosciences Inc Fourth Quarter Earnings Results for 2025 | 2026-03-09T00:00:00 |
| Spruce Biosciences Inc Annual Report for 2025 | 2026-03-09T00:00:00 |
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25T15:20:00 |
| Spruce Biosciences Inc Third Quarter Earnings Results for 2025 | 2025-11-10T00:00:00 |
| Spruce Biosciences Inc Second Quarter Earnings Results for 2025 | 2025-08-14T00:00:00 |
| Spruce Biosciences Inc Annual General Meeting for 2025 | 2025-06-09T10:00:00 |
| Spruce Biosciences Inc First Quarter Earnings Results for 2025 | 2025-05-06T00:00:00 |
| Corporate Update Conference Call | 2025-04-15T08:30:00 |
| Spruce Biosciences Inc Annual Report for 2024 | 2025-04-15T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.